jj1223, I have way too many shares not to hope you are correct.
Peregrine management knows they need a lot more money to fund Bavi in connection with the new immunotherapies. With Peregrine's history, including recent history, of drug development failure, I don't see retail investors giving Peregrine another chance. By the way there is a very big assumption here that Peregrine's paid researchers come back with positive reports.
If they do find promising results, going forward with Bavi makes some sense. If Peregrine can't attract a financially significant BP partnership, not to be confused with what we have been told about the AstraZeneca deal, I don't believe proceeding with Bavi is a wise course. Too much risk(wiping out shareholders) for a very uncertain reward.
Better to resign ourselves to owning a growing bio manufacturing company(Avid) than a bankrupt drug investigating company.
GLTA, Paul
News 
Market Data 
Discover 
